Edition:
United Kingdom

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

6.68USD
8:59pm GMT
Change (% chg)

$-0.27 (-3.88%)
Prev Close
$6.95
Open
$6.94
Day's High
$7.00
Day's Low
$6.64
Volume
37,444
Avg. Vol
22,684
52-wk High
$21.59
52-wk Low
$6.10

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $110.31
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage:

13 Nov 2017

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

19 Sep 2017

BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​

* Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​ Source text: (http://bit.ly/2vRDX2x) Further company coverage:

01 Sep 2017

Earnings vs. Estimates